July 20, 2011
Solos Endoscopy’s MammoViewÂ® System Proves Crucial to Early Breast Cancer Detection
BOSTON, July 20, 2011 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) MammoViewÃ® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoViewÃ® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
The Solos MammoViewÃ® system is currently in use at various teaching hospitals across the United States. Patients should be aware that mammary ductoscopy, utilizing the MammoViewÃ® system, is a means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging that can reveal evidence of the disease.According to a recent report in the journal Radiology, "The Swedish Two-County Trial" was the first study to demonstrate a drop in breast cancer mortality from solely screening with mammography. Researchers found that there were 30% fewer deaths caused by breast cancer in an invitation group (received an invitation to screening), compared to the usual care group (received usual care). For breast cancer detection, other than clinical and self-examination, women rely almost exclusively on mammography, which can have limitations. Mammography fails to detect up to 20% of cancer in women over 50 and up to 40% of cancer in younger women. When cancer is detected, the technology is so insensitive that typically, the smallest tumor size detected is approximately 1cm. At that size, a tumor has probably been growing, undetected, for nearly 8 years. The findings, coupled with the limitations, are significant in that mammary ductoscopy, as capable with the Solos MammoViewÃ® system, is designed to provide physicians the means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging can reveal evidence of the disease.
"Breast cancer doesn't discriminate; in 2007, 202,964 women in the United States were diagnosed with breast cancer and 40,598 women in the United States died from breast cancer, it can affect anyone," stated Bob Segersten, President of Solos Endoscopy, Inc. "Early detection is crucial to successful treatment and that screening really does save lives."
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.